Depressed Caucasians with Met allele of BDNF Val66Met polymorphism have more deleterious metabolic changes after antidepressant treatment than Val/Val

AbstractBackgroundThe brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with response to antidepressant drugs in depressed patients and with metabolic side effects after antipsychotic treatment. This study aims to assess the association between this polymorphism and insulin resistance after antidepressant treatment in depressed patients.MethodsOne hundred forty-eight Caucasian patients with a current unipolar major depressive episode (DSM IV-TR) were genotyped for the BDNF Val66Met polymorphism and assessed at baseline and after 3 and 6 months of antidepressant treatment for the ‘Homoeostasis model assessment of insulin resistance’ (HOMA-IR) index, a valid measure of insulin resistance based on fasting plasma insulinaemia and glycaemia. Because validity assumptions were fulfilled, data were analysed using analysis of variance for repeated measures.ResultsThe 52 (35%) Met carriers and 96 (65%) Val/Val patients were not different at baseline for clinical characteristics and HOMA-IR. A significant Val66Met × time interaction (p= 0.02), a significant time effect (p= 0.03) and a significant Val66Met effect (p= 0.0497) were shown for HOMA-IR. A significant Val66Met × time interaction (p= 0.01) and a significant time effect (p= 0.003) were shown for fasting glycaemia. HOMA-IR and fasting glycaemia changes after antidepressant treatment were significantly higher in Met carrier than in Val/Val patients (HOMA-IR changes: Met: 0.71 ± 3.29v.Val/Val: −0.16 ± 1.34,t= 2.3, df = 146,p= 0.02, glycaemia changes: Met: 0.09 ± 0.30v.Val/Val: 0.02 ± 0.16,t= −2.0, df = 146,p= 0.045).ConclusionsThe Met allele of the Val66Met BDNF polymorphism confers to depressed patients a higher risk of insulin-resistance after antidepressant treatment. These patients could benefit from specific monitoring of metabolism and preventive measures.

Download Full-text

Supplemental Material for BDNF Val66Met Polymorphism to Generalized Anxiety Disorder Pathways: Indirect Effects via Attenuated Parasympathetic Stress-Relaxation Reactivity

Journal of Abnormal Psychology ◽

10.1037/abn0000507.supp ◽

2020 ◽

Keyword(s):

Anxiety Disorder ◽

Stress Relaxation ◽

Generalized Anxiety Disorder ◽

Indirect Effects ◽

Generalized Anxiety ◽

Val66met Polymorphism ◽

Bdnf Val66met Polymorphism

Download Full-text

The Brain-Derived Neurotrophic Factor (BDNF) Val66Met polymorphism modulates the effects of serious life events on impulsive aggression in patients with Borderline Personality Disorder

Pharmacopsychiatry ◽

10.1055/s-0029-1240244 ◽

2009 ◽

Vol 42 (05) ◽

Author(s):

S Wagner ◽

Ö Baskaya ◽

K Lieb ◽

N Dahmen ◽

A Tadic

Keyword(s):

Borderline Personality Disorder ◽

Personality Disorder ◽

Life Events ◽

Neurotrophic Factor ◽

Brain Derived Neurotrophic Factor ◽

Borderline Personality ◽

Val66met Polymorphism ◽

Impulsive Aggression ◽

Bdnf Val66met Polymorphism ◽

The Brain

Download Full-text

Reduced glutamatergic metabolism in the anterior cingulate cortex in carriers of the Met-allele of the BDNF Val66Met polymorphism

10.26226/morressier.5971be80d462b80290b52367 ◽

2017 ◽

Author(s):

Louise Martens

Keyword(s):

Anterior Cingulate Cortex ◽

Cingulate Cortex ◽

Anterior Cingulate ◽

Val66met Polymorphism ◽

Bdnf Val66met Polymorphism

Download Full-text

Faculty Opinions recommendation of BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14213.471715 ◽

2006 ◽

Author(s):

Nick Ward

Keyword(s):

Motor Cortex ◽

Val66met Polymorphism ◽

Human Motor Cortex ◽

Dependent Plasticity ◽

Bdnf Val66met Polymorphism ◽

Human Motor

Download Full-text

The genetic influence of the brain-derived neurotrophic factor Val66Met polymorphism in chronic low back pain

Advances in Rheumatology ◽

10.1186/s42358-021-00183-7 ◽

2021 ◽

Vol 61 (1) ◽

Author(s):

Angela Shiratsu Yamada ◽

Flavia Tasmim Techera Antunes ◽

Camila Ferraz ◽

Alessandra Hubner de Souza ◽

Daniel Simon

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Chronic Low Back Pain ◽

Neurotrophic Factor ◽

Central Sensitization ◽

Low Back ◽

Bdnf Gene ◽

Val66met Polymorphism ◽

Bdnf Val66met Polymorphism ◽

The Brain

Abstract Background The Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene is a potential biomarker of vulnerability to pain. Thus, the present study aimed to investigate the association of this polymorphism with clinical and biopsychosocial factors in patients with chronic low back pain (CLBP). Methods A total of 107 individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, including the Brief Inventory of Pain, the Central Sensitization Inventory, the Roland Morris Disability Questionnaire, the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, the Survey of Pain Attitude-Brief, and the Hospital Anxiety and Depression Scale. All of the subjects were genotyped for the BDNF Val66Met polymorphism. Results The sample showed moderate scores of disability, central sensitization, and kinesiophobia, in addition to mild anxiety, hopelessness, and ruminant thoughts. No significant association was observed between the Val66Met polymorphism and the variables analyzed. Besides, there was no relationship between the BDNF Val66Met polymorphism with CSI, catastrophization, or disabilities that were generated by CLBP. Conclusion The results showed that the Val66Met polymorphism of the BDNF gene was not associated with clinical and biopsychosocial characteristics of CLBP in the sample studied.

Download Full-text